As Canada's health ministers meet in St. John's, nurses release report suggesting innovation rather than cuts is key to bringing stability to the system.
The monoclonal antibody omalizumab reduces the risk of exacerbations by about 25% over the course of a year among patients with more severe, persistent asthma.
